American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

…, M Khalighi, SI Choi, M Gogia, S Kafaja… - Arthritis care & …, 2012 - Wiley Online Library
In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60% …

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …

…, J Goldin, E Arriola, ER Volkmann, S Kafaja… - The lancet Respiratory …, 2016 - thelancet.com
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

…, JZ Forstot, DE Furst, S Kafaja… - The Lancet …, 2020 - thelancet.com
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …

[HTML][HTML] Myeloablative autologous stem-cell transplantation for severe scleroderma

…, C Hosing, S Forman, S Kafaja… - … England Journal of …, 2018 - Mass Medical Soc
Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …

Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator‐initiated, multicenter, double‐blind, randomized, placebo‐controlled trial

…, R Lafyatis, RW Simms, A Gill, S Kafaja… - Arthritis & …, 2020 - Wiley Online Library
Objective T cells play a key role in the pathogenesis of early systemic sclerosis. This study
was undertaken to assess the safety and efficacy of abatacept in patients with diffuse …

Reliability and minimal clinically important differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

S Kafaja, PJ Clements, H Wilhalme… - American journal of …, 2018 - atsjournals.org
Rationale: FVC percent predicted (FVC%) is the primary outcome measure in clinical trials
of systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over …

American College of Rheumatology report on reasonable use of musculoskeletal ultrasonography in rheumatology clinical practice

…, MA McMahon, J Grossman, S Kafaja… - Arthritis care & …, 2012 - Wiley Online Library
Musculoskeletal ultrasound (MSUS) has been embraced by many clinical rheumatologists,
researchers in the field of rheumatology, and other subspecialists who treat rheumatology …

Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition

…, A Afonso, O Distler, S Kafaja… - … of scleroderma and …, 2017 - journals.sagepub.com
Purpose There is a lack of a valid definition for skin ulcers in systemic sclerosis (SSc) to be
used in clinical trials. Our aim was to develop a consensus definition for SSc skin ulcers …

Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience

…, D Sayah, T Mahrer, DE Furst, S Kafaja… - Annals of the …, 2016 - atsjournals.org
Rationale: Consideration of lung transplantation in patients with systemic sclerosis (SSc)
remains guarded, often due to the concern for esophageal dysfunction and the associated …

The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts

…, M Hudson, SR Johnson, N Jones, S Kafaja… - …, 2018 - academic.oup.com
Objectives The Scleroderma Patient-centered Intervention Network (SPIN) Cohort is a web-based
cohort designed to collect patient-reported outcomes at regular intervals as a …